1. Brand KD, Doherty M, Lohmander LS. Osteoarthritis. Oxford Univ Press 1998.
2. Reginster JY. The prevalence and burder of arthritis. Rheumatology 2002; 41: 3–6.
3. Lawrence RS, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the US. Arthr Rheum 1998; 41: 778–99.
4. Фоломеева О.М., Лебедева Л.С., Ушакова М.А. Инвалидность, обусловленная ревматическими заболеваниями, среди жителей Российской Федерации. Научно-практ. ревматол. 2001; 1: 15–21.
5. Эрдес Ш.Ф., Фоломеева О.М. Ревматические заболевания и инвалидность взрослого населения Российской Федерации. Научно-практ. ревматол. 2007; 4: 4–10.
6. Zhang W, Nuki G, Moskowitz RW et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarth Cartil 2010; 18: 476–99.
7. Ревматология. Клинические рекомендации. М.: ГЭОТАР-Медиа, 2010.
8. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical NON-Steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta- analysis of randomized controlled trials. BMJ 2004; 329: 324–6.
9. Evans JM, MacDonald TM. Tolerability of topical NSAIDs in the elderly: do they really convey a safety advantage? Drugs Aging 1996; 9: 101–8.